Dabrafenib is one of the most widely used of the new generation of targeted anti-cancer drugs. However, its therapeutic window varies for different patients and so there is an unmet need for methods to monitor the dose of drug which the patient receives and at the specific site where it acts. In the case of cancers, it is critical to measure the concentration of drug not just in the bloodstream overall, but in or near tumours, as these will not be the same over multiple time periods. A novel sensor based on an optical fibre long period grating (LPG) modified with a molecular imprinted polymer (MIP) has been developed with the ultimate aim of achieving minimally invasive measurements of Dabrafenib at the tumour site. A molecularly imprinted polymer specific for Dabrafenib was coated on a methacryloylalkoxysilane-functionalised optical fibre long period grating. In vitro experimental results demonstrate that the Dabrafenib sensitivity is 15.2 pm (μg mL⁻¹)⁻¹ (R² = 0.993) with a limit of detection (LoD) of 74.4 μg mL⁻¹ in serum solution. Moreover, the proposed sensor shows selective response to Dabrafenib over structurally similar 2-Aminoquinoline.

中文翻译：

---

用于达拉非尼剂量检测的表面聚合物印迹光纤传感器。

达布拉非尼是新一代靶向抗癌药物中使用最广泛的药物之一。然而，其治疗窗口因不同患者而异，因此对监测患者所接受的药物剂量及其作用的特定部位的方法存在未满足的需求。在癌症的情况下，至关重要的是不仅要测量整个血液中的药物浓度，还要测量肿瘤中或附近的药物浓度，因为在多个时间段内这些浓度将不同。已经开发出一种基于用分子印迹聚合物（MIP）修饰的光纤长周期光栅（LPG）的新型传感器，其最终目的是在肿瘤部位实现达拉非尼的微创测量。体外实验结果表明，达布拉非尼的敏感性为15.2 pm（μgmL ^-1）^-1（R ² = 0.993），血清溶液中的检测限（LoD）为74.4μgmL ^-1。此外，所提出的传感器显示出对达拉非尼的选择性反应，其对结构相似的2-氨基喹啉有选择性。